Swiss biotech firm, Actelion (VTX: ATLN) on Tuesday raised its full-year 2015 core-earnings outlook on the back of better than estimated product sales, while posting a drop in second quarter earnings.
The company reported earnings of 1.12 Swiss francs per share compared with 2.53 francs a year ago.
Europe's largest biotech company, posted second quarter operating income of 154.02 million Swiss francs ($160.20 million) against 194.32 million francs ($ 202.09 million) a year earlier.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze